No Data
Harbin Medisan Pharmaceutical (002900.SZ): A total of 11.0817 million yuan in government subsidies received.
Gelonghui, December 30丨Harbin Medisan Pharmaceutical (002900.SZ) announced that from November 14, 2024, to December 29, 2024, the company and Peking Harbin Medisan Technology Co., Ltd. have received a total of 11.0817 million yuan in government subsidies.
Harbin Medisan Pharmaceutical (002900.SZ): Some pharmaceuticals are proposed to be awarded in centralized procurement.
On December 13, Gelonghui reported that Harbin Medisan Pharmaceutical (002900.SZ) announced that the company and its wholly-owned subsidiary Lanxi Harbin Medisan Pharmaceutical Co., Ltd. (hereinafter referred to as "Lanxi Pharmaceutical") recently participated in the bidding for the 10th national centralized procurement organized by the National Organization of Pharmaceutical Concentrated Procurement and Use Joint Procurement Office (hereinafter referred to as "Joint Procurement Office"). The company's pharmaceutical products, namely Esmolol Hydrochloride Injection, Theobromine Injection, and Potassium Chloride Injection, as well as Lanxi Pharmaceutical's product, Tandedrone Citrate Tablets, are expected to win the bid in this centralized procurement.
Harbin Medisan Pharmaceutical (002900.SZ): Received a total of 25.5098 million yuan in government subsidies.
Gelonghui, on November 18, announced that Harbin Medisan Pharmaceutical (002900.SZ) disclosed that its wholly-owned subsidiaries, Lanxi Harbin Medisan Pharmaceutical Co., Ltd. (hereinafter referred to as "Lanxi Pharmaceutical"), Guangzhou Harbin Medisan Biotechnology Co., Ltd. (hereinafter referred to as "Guangzhou Harbin Medisan"), Lanxi Harbin Medisan Medicine Co., Ltd. (hereinafter referred to as "Lanxi Medicine"), Harbin Sanlian Lide Biotechnology Co., Ltd. (hereinafter referred to as "Lide Biotechnology"), Lingbao Harbin Medisan Biopharmaceutical Co., Ltd. (hereinafter referred to as "Lingbao Harbin Medisan"), and Peking Harbin Medisan Technology Co., Ltd. (hereinafter referred to as "Peking Technology") will be active from February 4, 2024 to...
There Might Be More To Harbin Medisan Pharmaceutical's (SZSE:002900) Story Than Just Weak Earnings
Harbin Medisan Pharmaceutical (002900.SZ): The pharmaceutical sodium bicarbonate injection has passed the consistency evaluation.
On October 28th, Harbin Medisan Pharmaceutical (002900.SZ) announced that the company recently received the drug supplementary application approval notice issued by the National Medical Products Administration. The company's pharmaceutical Sodium Bicarbonate Injection passed the generic drug quality and efficacy consistency evaluation (referred to as "consistency evaluation"). Sodium Bicarbonate Injection is mainly used to treat metabolic acidosis, alkalinize urine, and intravenous infusion has a nonspecific therapeutic effect on certain drug intoxications.
Kazakh Triptych: Report for the third quarter of 2024